infanrix-hib vakcina
glaxosmithkline kft. - vakcina (bakteriális) -
indapamid ozone 1,5 mg retard tabletta
labormed pharma s.a. - indapamide -
lendacin 2 g por injekcióhoz
eu pharma kft. - ceftriaxon -
gambro d-294 savas bikarbonát hemodialízis koncentrátum
gambro eü. szolgáltató és kereskedelmi kft. - electrolits -
philogastro
ab-original kereskedelmi és szolgáltató kft. - echinacea angustifolia d1, foeniculum vulgare, tengeri moszat kivonat, aloe ferox levelének glikolos kivonata, olajfa kivonat, orvosizilíz-gyökér - belsoleges oldat - permethrin, combinations - ló
folteltávolító spray lovak részére
tízpróba magyarország kereskedelmi kft. - csirkeanaemia-vírus - külsoleges oldatos spray - chicken anaemia vaccine - ló
gambro d-210 savas bikarbonát hemodialízis koncentrátum
gambro eü. szolgáltató és kereskedelmi kft. - electrolits -
gambro d-710 savas bikarbonát hemodialízis koncentrátum
gambro eü. szolgáltató és kereskedelmi kft. - electrolits -
enhertu
daiichi sankyo europe gmbh - trastuzumab deruxtecan - mellnövekedés - daganatellenes szerek - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.